All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

6

2023 to 2026

Breakthrough

3

Accelerated

0

Priority review

4

Orphan

3

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202300
202421
202521
202600

6 approvals

Newest first. Hover a badge for what it means.

  • Exdensur (Depemokimab-Ulaa) · Glaxosmithkline LLCDec 16, 2025
    Original approval · BLA 761458NovelApproval letter

    To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapy

  • Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
    Original approval · NDA 218764NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat idiopathic pulmonary fibrosis

  • Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
    Original approval · NDA 217673NovelBreakthrough therapyPriority reviewApproval letter

    To treat non-cystic fibrosis bronchiectasis

  • Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INCDec 20, 2024
    Original approval · NDA 218730NovelPriority reviewOrphanApproval letter

    For the treatment of cystic fibrosis (CF) in patients 6 years of age and older

  • Ohtuvayre (Ensifentrine) · MsdJun 26, 2024
    Original approval · NDA 217389NovelApproval letter

    To treat chronic obstructive pulmonary disease

  • Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
    Original approval · BLA 761363NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat pulmonary arterial hypertension

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.